Fig. 4. CD27+IgD+ B cell amounts are
increased after treatment of human SLE. (A) Flow cytometry assessment of
CD27+IgD+ B cell levels
pre-treatment and at 4 weeks post-treatment initiation. (B) SLEDAI
scores before and after treatment in SLE patients
(n=12). (C)
CD27+IgD+ B cell percentages in SLE
patients before and after treatment (n=12). (*P<0.05,
**P<0.01).